13F Holdings
中文EN

SPRO Spero Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1701108 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY2.5%
TTM net income YoY32.7%
TTM EPS YoY36.7%
Revenue 3-yr CAGR-18.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-67.3%
Net margin-71.0%
FCF margin—
EBITDA margin—

Returns

ROE-216.4%
ROA-35.9%
ROIC (approx.)—
Asset turnover0.51x

Leverage & solvency

Liabilities / assets99.3%
Debt / equity0.00x
Current ratio1.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio13.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY2022*2022-12-31FY20212021-12-31
Income statement
Revenue$66.80M$47.98M$103.78M$53.51M$18.26M
R&D expense$38.47M$96.76M$51.44M$47.59M$64.53M
SG&A expense$21.18M$23.70M$25.55M$36.48M$41.70M
Operating income$6.31M-$73.36M$21.48M-$42.20M-$87.97M
Pretax income$8.83M-$68.57M$25.40M-$46.41M-$89.76M
Income tax$261,000$0$2.60M$0$0
Net income$8.57M-$68.57M$22.81M-$46.41M-$89.80M
EBITDA$6.31M-$73.36M$21.85M-$41.33M-$87.33M
EPS (basic)0.15-1.270.43-1.23-2.91
EPS (diluted)0.15-1.270.43-1.23-2.91
Weighted avg. shares (diluted)59.04M54.04M52.99M37.59M30.90M
Balance sheet
Cash & equivalents$40.27M$52.89M$76.33M$109.11M$112.58M
Short-term investments———$0$33.82M
Current assets$67.29M$107.28M$131.21M$113.57M$157.87M
PP&E, net—$0$2,000$368,000$1.03M
Total assets$68.92M$110.54M$182.39M$124.80M$171.07M
Current liabilities$8.87M$49.07M$37.15M$21.65M$18.67M
Total liabilities$9.90M$64.42M$75.50M$48.87M$82.78M
Shareholders' equity$59.02M$46.12M$106.89M$75.93M$88.29M
Shares outstanding56.41M54.59M53.00M52.46M32.39M
Cash flow statement
Operating cash flow-$12.62M-$23.44M-$32.99M-$7.73M-$64.35M
Investing cash flow——$0$33.81M$7.67M
Financing cash flow—$0$221,000-$29.55M$84.05M
Depreciation & amortization$0$2,000$367,000$869,000$646,000
Stock-based compensation$4.33M$7.79M$7.93M$9.12M$9.43M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.